GlassScriptPhysician profile
Amanda Jones
NPI 1003402496
$4,140.20
in general payments reported to CMS, 2019-2025
34 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,960 · 2022: $287 · 2023: $13.07 · 2024: $168 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $342.40 | 2021-2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $334.08 | 2021-2022 | |
| Abbvie INC. | $302.81 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $299.59 | 2021 | |
| Lilly USA, LLC | $255.87 | 2021 | |
| Alkermes, INC. | $247.16 | 2021-2025 | Aristada, Lybalvi |
| Biohaven Pharmaceuticals, INC. | $214.68 | 2021 | |
| Galderma Laboratories, L.P. | $202.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $183.41 | 2021 | |
| Novo Nordisk INC | $181.43 | 2021 | |
| Sanofi-Aventis U.S. LLC | $178.46 | 2021-2022 | |
| Lundbeck LLC | $166.81 | 2025 | Abilify Maintena |
| Amgen INC. | $148.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $130.01 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $128.40 | 2021-2025 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $118.93 | 2021 | |
| Medtronic, INC. | $95.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.24 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.83 | 2021 | |
| Pfizer INC. | $52.56 | 2021-2022 | |
| Eisai INC. | $38.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.11 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.03 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.64 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.59 | 2021-2022 | |
| Clarus Therapeutics INC. | $24.28 | 2021 | |
| Baxter Healthcare | $23.81 | 2022 | |
| Boston Scientific Corporation | $19.79 | 2025 | General - Therapies |
| Supernus Pharmaceuticals, INC. | $16.57 | 2021 | |
| Mylan Specialty L.P. | $16.43 | 2021 | |
| Biogen, INC. | $13.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.